The Berlin-based startup, Dopavision, is pioneering the development of digital therapeutics in ophthalmology by developing a digital therapeutic for childhood myopia. Their technology delivers light stimulation to specific photosensitive cells on the retina which modulate dopamine, a neurotransmitter that regulates eye growth. Dopavision aims to provide a clinically validated therapy to help fight the global myopia crisis, which is expected to reach a prevalence of 50% by 2050. The company has raised €14.7 million in private equity and public grants, and is supported by the German Federal Ministry of Education and Research. The proceeds from the €12 million Series A financing round will be used to fund the clinical development of their lead product, MyopiaX®, as well as ongoing scientific research and product development activities.